Nutritional product maker British Biologicals will invest about Rs 100 crore over the next two years on marketing and other promotional expenses in India, in tune with its plan to achieve a Rs 350-crore turnover by 2012.
"We are in talks with innovative firms such as US-based DSM and UK-based Next Nutrition to launch more Nutraceutical products in therapeutic areas such as diabetes and cancers, in India," British Biological Managing Director VS Reddy said.
The company is also expanding its distribution network across the country and plans to take large scale marketing activity across the country to promote its product.
When asked about the investments Reddy said, "We will be investing close to Rs 100 crore in these activities over the next two years."
Nutraceutical products are the basically food supplements and are designed in keeping with the requirements in therapeutic areas, Reddy said.
The company has recently announced the launch of 'Cardiopro', a cholesterol lowering Nutraceutical product in cardio vascular therapeutic segment, in association with UK-based research firm Horphag Research.
The company has clocked a turnover of Rs 130 crore in the last fiscal and is targeting a sales of Rs 350 crore by 2012.